Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01817426
Other study ID # 02MA
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2013
Est. completion date May 2020

Study information

Verified date March 2022
Source Copenhagen University Hospital at Herlev
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether infliximab can favourably and safely be discontinued in patients with Crohn's disease in sustained complete clinical, biochemical, and endoscopic remission on infliximab. Further to examine the clinical utility of measuring levels/activity of infliximab and activity of anti-infliximab Ab in patients in sustained complete remission, in order to investigate whether pharmacoimmunological data can predict the clinical outcome and rationalize therapeutic management of these patients with respect to continuation or discontinuation of infliximab therapy. Additional, to investigate the optimal time-point, out of three, to measure this activity.


Description:

Recent guidelines for the management of Crohn's disease conclude that currently available data are insufficient to make firm recommendations on when and in whom to stop TNF-α antibody (TNF-α Ab) treatment after having obtained clinical remission. Further, the term "remission" is not well uniformly defined and may incorporate one or more features such as clinical remission, as assessed by CDAI, biochemical remission, endoscopical remission etc. The recently published prospective STORI study of 115 patients with luminal Crohn's disease reported that 56% of patients with Crohn's disease who had discontinued infliximab (IFX) while in clinical remission, maintained remission one year after discontinuation of therapy. Predictors of relapse included certain clinical features as well as objective biochemical and endoscopical markers of disease activity. Consistent with these data, we have recently reported that 61% of our own patients with Crohn's disease, who discontinued IFX while in complete clinical, steroid free IFX induced remission, maintained remission after one year; and half the patients were still in remission after nearly two years (median 680 days [412-948]). A prospective randomized study of patients with Crohn's disease is necessary to confirm and extend the limited findings above, and assess whether IFX can be safely discontinued in a selected subgroup of patients with complete clinical, biochemical, and endoscopical remission. Methods: Study design: Prospective, double-blinded, randomized, placebo-controlled, Danish multi-center study with estimated seven Danish participating centers. Patients and treating physicians are blinded for the type of intervention. Study population: Patients with luminal Crohn's disease in sustained complete remission on IFX. Study treatment: Patients are randomized to either continue IFX treatment at an unchanged dosage and frequency, or alternatively to receive matching placebo. All patients will be graded for disease activity (Crohn's Disease Activity Index (CDAI), biochemical parameters, endoscopy, and/or MRI). Following screening and inclusion patients are seen after four weeks, and then every eight weeks. Endpoints are assessed at 48 weeks. Investigators will, as explorative analyses, examine the clinical utility of measuring IFX levels and antibodies against IFX in patients with complete remission, in order to investigate whether pharmacoimmunological data can predict the clinical outcome and rationalize therapeutic management of these patients with respect to continuation or discontinuation of IFX therapy. Additional, investigators will investigate the optimal time-point out of three to measure this activity. Patients will on the day of infusion have three blood samples drawn: one just before infusion (trough), one right after the infusion (obtained from the other arm)(peak) and one an hour after infusion (C1). Samples will be measured by common solid - and fluid phase assays for this purpose, e.g. Reporter Gene Assay (RGA).


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date May 2020
Est. primary completion date May 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Luminal Crohn's disease defined according to standardized diagnostic criteria. - Age = 18 years. - IFX induction treatment week 0, 2, 6 followed by maintenance therapy. - IFX treatment length minimum 12 months. Episodic therapy with IFX pause > 12 weeks is not accepted within the last year. The treatment interval in the last three months has to be of 6-10 weeks. - Complete remission defined as: - CDAI score < 150 and - Biochemical remission, and - No other signs of disease activity as evaluated by endoscopic examination or by magnetic resonance imaging (MRI). - Stable remission, judged by the treating physician, at two consecutive treatments visits corresponding 2 scheduled IFX infusions. Thus, the first visit is during IFX maintaining therapy (screening visit). The second visit is at time of inclusion corresponding time of next scheduled IFX infusion (i.e. after ˜ 8 weeks). - No use of oral steroids within 3 months prior to inclusion. - Concomitant therapy with other immune suppressants, except steroids, is allowed. The dosage and frequency must have been stable three months prior to inclusion and must remain stable throughout the study period. Exclusion Criteria: - Initial indication for IFX being predominantly fistulizing perianal disease. - Any contraindications for continuing IFX treatment, including prior acute or delayed infusion reaction to a TNF- inhibiting agent, any active infection requiring parenteral or oral antibiotic treatment, known infection with tuberculosis, human immunodeficiency virus (HIV) or hepatitis virus. - Any condition including physician finds incompatible with participation in the study or the patient being unwilling or unable to follow protocol requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Infliximab

Other:
Placebo


Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus Aarhus C
Denmark Bispebjerg Hospital Copenhagen Copenhagen NV
Denmark Herlev Hospital, department of gastroenterology medical section Herlev
Denmark Hospital enheden vest Herning Herning
Denmark Hvidovre Hospital Hvidovre
Denmark Nykøbing F. Sygehus Nykøbing Falster Nykøbing
Denmark Odense University hospital Odense Odense C
Denmark Silkeborg Regional Hospital, Diagnostic Center Silkeborg
Denmark Slagelse Sygehus Slagelse
Finland Helsinki University Hospital and University of Helsinki Helsinki
Norway Akerhus University Hospital Oslo
Sweden Skane University Hospital Lund
Sweden Karolinska Institute Stockholm

Sponsors (1)

Lead Sponsor Collaborator
Copenhagen University Hospital at Herlev

Countries where clinical trial is conducted

Denmark,  Finland,  Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to relapse after discontinuation of IFX Relapse defined as CDAI >150 and an increase in CDAI from baseline >70 over 2 consecutive weeks (or definitive relapse as judged by treating physician) 48 weeks
Secondary Time to loss of remission Loss of remission defined as CDAI > 150 48 weeks
Secondary Proportion of patients who maintain clinical remission Defined as CDAI<150 48 weeks
Secondary Proportion of patients who maintain clinical and endoscopic remission Defined as CDAI<150 and SES-CD = 2 48 weeks
Secondary Proportion of patients who experience relapse (more stringent definition) Relapse defined as CDAI >150 and an increase in CDAI from baseline >100 over 2 consecutive weeks (or definitive relapse as judged by treating physician) 48 weeks
Secondary Proportion of patients who experience relapse Relapse defined as CDAI >150 and an increase in CDAI from baseline >70 over 2 consecutive weeks (or definitive relapse as judged by treating physician)drug therapy. 48 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT05294107 - Intestinal Organoids N/A
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Recruiting NCT05906576 - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Phase 4
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3